MichaelOffinMD

Hematologic Oncology, Thoracic Cancer

Thoracic Oncology Attending at Memorial Sloan Kettering Cancer Center

Overview of Dr. Offin

Dr. Michael Offin is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from Rutgers New Jersey Medical School and has been in practice 4 years. He is one of 494 doctors at Memorial Sloan Kettering Cancer Center and one of 494 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 70 publications and over 500 citings.

Office
530 East 74th Street
New York, NY 10021
Book by Phone+1(917) 746-8383

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2016 - 2019
University of Pennsylvania Health SystemResidency, Internal Medicine, 2013 - 2016
Rutgers New Jersey Medical SchoolClass of 2013

Certifications & Licensure

FL State Medical License 2021 - Present
NJ State Medical License 2019 - 2025
NY State Medical License 2016 - 2025
CT State Medical License 2023 - 2024
PA State Medical License 2015 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Start of enrollment: 2016 Sep 29
Completed
Phase 1
A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma Start of enrollment: 2021 Aug 10
Recruiting
Phase 1
Roles: Contact
A Study of Pembrolizumab and Cryoablation in People With Mesothelioma Start of enrollment: 2021 Sep 24
Completed
Phase 1
Roles: Principal Investigator, Contact
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma Start of enrollment: 2019 Nov 12
Active, not recruiting
Phase 1
Roles: Principal Investigator, Contact
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma Start of enrollment: 2019 Jul 24
Active, not recruiting
Phase 1
Roles: Contact
Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression Start of enrollment: 2019 Apr 16
Completed
Phase 1
Roles: Principal Investigator, Contact
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors Start of enrollment: 2021 Aug 04
Recruiting
Phase 1
Roles: Principal Investigator, Contact
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma Start of enrollment: 2023 Sep 21
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

23 citations
Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset.
Christopher A Febres-Aldana, Jason C Chang, Ryan Ptashkin, Yuhan Wang, Erika Gedvilaite
Clinical Cancer Research. 2022-11-01
168 citations
Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer
Joseph M. Chan, Álvaro Quintanal-Villalonga, Vianne R. Gao, Yubin Xie, Viola Allaj
Cancer Cell. 2021-11-08
67 citations
Multi-omic analysis of lung tumors defines pathways activated in neuroendocrine transformation.
Álvaro Quintanal-Villalonga, Hirokazu Taniguchi, Yingqian Zhan, Maysun Hasan, Shweta S Chavan
Cancer Discovery. 2021-06-21

Journal Articles

PD-L1 Expression, Tumor Mutational Burden, and Response to Immunotherapy in Patients with MET Exon 14 Altered Lung Cancers
G J Riely, J Dienstag, C Mrad, J K Sabari, M G Kris, K C Arbour, D F Halpenny, N Rekhtman, R Chen, A J Plodkowski, P K Paik, B T Li, I Bergagnini, M D Offin, C M Rudin..., Annals of Oncology

Lectures

Efficacy of ramucirumab and docetaxel given either before or after immune checkpoint inhibitors in patients with lung cancers.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

MSK Research Highlights, November 23, 2022November 23rd, 2022
Researchers Open Phase I Clinical Trial of Cryoablation with KeytrudaOctober 14th, 2021
ASCO 2021 Research Roundup: Focus on ImmunotherapyJune 7th, 2021
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member